|
1
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zagzag D, Lukyanov Y, Lan L, Ali MA,
Esencay M, Mendez O, Yee H, Voura EB and Newcomb EW:
Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in
glioblastoma: Implications for angiogenesis and glioma cell
invasion. Lab Invest. 86:1221–1232. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brat DJ, Castellano-Sanchez AA, Hunter SB,
Pecot M, Cohen C, Hammond EH, Devi SN, Kaur B and Van Meir EG:
Pseudopalisades in glioblastoma are hypoxic, express extracellular
matrix proteases and are formed by an actively migrating cell
population. Cancer Res. 64:920–927. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brat DJ and Van Meir EG: Vaso-occlusive
and prothrombotic mechanisms associated with tumor hypoxia,
necrosis, and accelerated growth in glioblastoma. Lab Invest.
84:397–405. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harris AL: Hypoxia-a key regulatory factor
in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calin GA, Ferracin M, Cimmino A, Di Leva
G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et
al: A MicroRNA signature associated with prognosis and progression
in chronic lymphocytic leukemia. N Engl J Med. 353:1793–1801. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bentwich I, Avniel A, Karov Y, Aharonov R,
Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, et al:
Identification of hundreds of conserved and nonconserved human
microRNAs. Nature Genet. 37:766–770. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Krek A, Grün D, Poy MN, Wolf R, Rosenberg
L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M
and Rajewsky N: Combinatorial microRNA target predictions. Nat
Genet. 37:495–500. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lewis BP, Shih IH, Jones-Rhoades MW,
Bartel DP and Burge CB: Prediction of mammalian microRNA targets.
Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kulshreshtha R, Ferracin M, Wojcik SE,
Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM,
Negrini M, et al: A microRNA signature of hypoxia. Mol Cell Biol.
27:1859–1867. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ali N, Mah N, McLoughlin P and Costello
CM: Identification of a hypoxia-responsive microRNA signature in
lung endothelial cells. Irish J Med Sci. 181:S4142012.
|
|
13
|
Qu K, Lin T, Pang Q, Liu T, Wang Z, Tai M,
Meng F, Zhang J, Wan Y, Mao P, et al: Extracellular miRNA-21 as a
novel biomarker in glioma: Evidence from meta-analysis, clinical
validation and experimental investigations. Oncotarget.
7:33994–34010. 2016.PubMed/NCBI
|
|
14
|
Shi R, Wang PY, Li XY, Chen JX, Li Y,
Zhang XZ, Zhang CG, Jiang T, Li WB, Ding W and Cheng SJ: Exosomal
levels of miRNA-21 from cerebrospinal fluids associated with poor
prognosis and tumor recurrence of glioma patients. Oncotarget.
6:26971–26981. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Põlajeva J, Swartling FJ, Jiang Y, Singh
U, Pietras K, Uhrbom L, Westermark B and Roswall P: miRNA-21 is
developmentally regulated in mouse brain and is co-expressed with
SOX2 in glioma. BMC Cancer. 12:3782012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gabriely G, Wurdinger T, Kesari S, Esau
CC, Burchard J, Linsley PS and Krichevsky AM: MicroRNA 21 promotes
glioma invasion by targeting matrix metalloproteinase regulators.
Mol Cell Biol. 28:5369–5380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang N, Hui L, Wang Y, Yang H and Jiang X:
SOX2 promotes the migration and invasion of laryngeal cancer cells
by induction of MMP-2 via the PI3K/Akt/mTOR pathway. Oncol Rep.
31:2651–2659. 2014.PubMed/NCBI
|
|
18
|
Yang N, Hui L, Wang Y, Yang H and Jiang X:
Overexpression of SOX2 promotes migration, invasion, and
epithelial-mesenchymal transition through the Wnt/β-catenin pathway
in laryngeal cancer Hep-2 cells. Tumour Biol. 35:7965–7973. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen S, Xu Y, Chen Y, Li X, Mou W, Wang L,
Liu Y, Reisfeld RA, Xiang R, Lv D and Li N: SOX2 gene regulates the
transcriptional network of oncogenes and affects tumorigenesis of
human lung cancer cells. PloS One. 7:e363262012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Steeg PS: Tumor metastasis: Mechanistic
insights and clinical challenges. Nat Med. 12:895–904. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bass AJ, Watanabe H, Mermel CH, Yu S,
Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, et
al: SOX2 is an amplified lineage-survival oncogene in lung and
esophageal squamous cell carcinomas. Nat Genet. 41:1238–1242. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Annovazzi L, Mellai M, Caldera V, Valente
G and Schiffer D: SOX2 expression and amplification in gliomas and
glioma cell lines. Cancer Genomics Proteomics. 8:139–147.
2011.PubMed/NCBI
|
|
24
|
Gangemi RM, Griffero F, Marubbi D, Perera
M, Capra MC, Malatesta P, Ravetti GL, Zona GL and Daga A: SOX2
silencing in glioblastoma tumor-initiating cells causes stop of
proliferation and loss of tumorigenicity. Stem cells. 27:40–48.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Heddleston JM, Li Z, Lathia JD, Bao S,
Hjelmeland AB and Rich JN: Hypoxia inducible factors in cancer stem
cells. Br J Cancer. 102:789–795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hall CL, Bafico A, Dai J, Aaronson SA and
Keller ET: Prostate cancer cells promote osteoblastic bone
metastases through Wnts. Cancer Res. 65:7554–7560. 2005.PubMed/NCBI
|
|
27
|
Osawa T and Shibuya M: Targeting cancer
cells resistant to hypoxia and nutrient starvation to improve
anti-angiogeneic therapy. Cell Cycle. 12:2519–2520. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wilson WR and Hay MP: Targeting hypoxia in
cancer therapy. Nat Rev Cancer. 11:393–410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Melillo G: Targeting hypoxia cell
signaling for cancer therapy. Cancer Metastasis Rev. 26:341–352.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ambros V: microRNAs: Tiny regulators with
great potential. Cell. 107:823–826. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang D, Qiu C, Zhang H, Wang J, Cui Q and
Yin Y: Human microRNA oncogenes and tumor suppressors show
significantly different biological patterns: From functions to
targets. PloS One. 5(pii): e130672010.PubMed/NCBI
|
|
32
|
Si ML, Zhu S, Wu H, Lu Z, Wu F and Mo YY:
miR-21-mediated tumor growth. Oncogene. 26:2799–2803. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ben-Porath I, Thomson MW, Carey VJ, Ge R,
Bell GW, Regev A and Weinberg RA: An embryonic stem cell-like gene
expression signature in poorly differentiated aggressive human
tumors. Nat Genet. 40:499–507. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Berezovsky AD, Poisson LM, Cherba D, Webb
CP, Transou AD, Lemke NW, Hong X, Hasselbach LA, Irtenkauf SM,
Mikkelsen T and deCarvalho AC: Sox2 promotes malignancy in
glioblastoma by regulating plasticity and astrocytic
differentiation. Neoplasia. 16:193–206. 206.e119-e125, 2014.
|
|
35
|
Yang N, Hui L, Wang Y, Yang H and Jiang X:
Overexpression of SOX2 promotes migration, invasion, and
epithelial-mesenchymal transition through the Wnt/β-catenin pathway
in laryngeal cancer Hep-2 cells. Tumour Biol. 35:7965–7673. 2014.
View Article : Google Scholar : PubMed/NCBI
|
